A Phase 2/3 interventional study of SPM 962 and placebo in Early Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-03-19.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 16th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 2 in phase 2/3, and was the 13th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2007.
This study's enrollment of 180 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 2 in phase 2/3, and was the 3rd registered.
Otsuka Holdings Co., Ltd.’s Parkinson Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 12 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPM 962
Drug: placebo
transdermal application, 1 time per day
transdermal application, 1 time per day
Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3
Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: baseline, end of maintenance period
Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period
Time frame: baseline, end of maintenance period
Mean Change in UPDRS Part 2 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, every two weeks
Efficacy Rate in UPDRS Part 2 Sum Score
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.
Time frame: Baseline, every two weeks
UPDRS Part 3 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, every two weeks
Efficacy Rate in UPDRS Part 3 Sum Score
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.
Time frame: Baseline, every two weeks
UPDRS Part 1 Sum Score
MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, every two weeks
UPDRS Part 4 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, every two weeks
Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4
Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, every two weeks
The Modified Hoehn and Yahr Stage
Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period. The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.
Time frame: Baseline, end of maintenance period
| Milestone | SPM962 | Placebo |
|---|---|---|
| Started | 90 | 90 |
| Completed | 75 | 80 |
| Not completed | 15 | 10 |
| Withdrew: Adverse event | 10 | 5 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Physician decision | 1 | 0 |
Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM962 | Placebo |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3 | -8.4 ± 9.7 | -4.1 ± 8.2 |
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period
| Percentage of participants | SPM962 | Placebo |
|---|---|---|
| ≥20% decrease | 71.6 (62.2 to 81.0) | 40.9 (30.6 to 51.3) |
| ≥30% decrease | 55.7 (45.3 to 66.1) | 29.5 (20.0 to 39.1) |
Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM962 | Placebo |
|---|---|---|
| Week 2 | -0.6 ± 2.1 | -0.5 ± 1.3 |
| Week 4 | -1.2 ± 2.7 | -1.0 ± 1.9 |
| Week 6 | -1.6 ± 2.9 | -1.4 ± 2.1 |
| Week 8 | -1.6 ± 3.3 | -1.3 ± 2.4 |
| Week 10 | -1.7 ± 3.2 | -1.2 ± 2.7 |
| Week 12 | -1.8 ± 3.2 | -1.1 ± 2.9 |
| End of maintenance period | -1.8 ± 3.3 | -1.1 ± 2.9 |
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.
| Percentage of participants | SPM962 | Placebo |
|---|---|---|
| ≥20% decrease (Week 2) | 36.4 (26.3 to 46.4) | 13.6 (6.5 to 20.8) |
| ≥20% decrease (Week 4) | 46.6 (36.2 to 57.0) | 34.1 (24.2 to 44.0) |
| ≥20% decrease (Week 6) | 52.3 (41.8 to 62.7) | 40.9 (30.6 to 51.2) |
| ≥20% decrease (Week 8) | 56.8 (46.5 to 67.2) | 43.2 (32.8 to 53.5) |
| ≥20% decrease (Week 10) | 58.0 (47.6 to 68.3) | 38.6 (28.5 to 48.8) |
| ≥20% decrease (Week 12) | 61.4 (51.2 to 71.5) | 39.8 (29.5 to 50.0) |
| ≥20% decrease (End of maintenance period) | 60.2 (50.0 to 70.5) | 39.8 (29.5 to 50.0) |
| ≥30% decrease (Week 2) | 20.5 (12.0 to 28.9) | 13.6 (6.5 to 20.8) |
| ≥30% decrease (Week 4) | 36.4 (26.3 to 46.4) | 19.3 (11.1 to 27.6) |
| ≥30% decrease (Week 6) | 43.2 (32.8 to 53.5) | 28.4 (19.0 to 37.8) |
| ≥30% decrease (Week 8) | 43.2 (32.8 to 53.5) | 25.0 (16.0 to 34.0) |
| ≥30% decrease (Week 10) | 43.2 (32.8 to 53.5) | 29.5 (20.0 to 39.1) |
| ≥30% decrease (Week 12) | 48.9 (38.4 to 59.3) | 26.1 (17.0 to 35.3) |
| ≥30% decrease (End of maintenance period) | 48.9 (38.4 to 59.3) | 26.1 (17.0 to 35.3) |
Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM962 | Placebo |
|---|---|---|
| Week 2 | -2.6 ± 4.2 | -1.7 ± 3.9 |
| Week 4 | -4.3 ± 5.2 | -2.7 ± 4.7 |
| Week 6 | -5.7 ± 6.3 | -3.3 ± 5.3 |
| Week 8 | -6.1 ± 6.7 | -3.3 ± 5.8 |
| Week 10 | -6.4 ± 6.7 | -3.4 ± 5.8 |
| Week 12 | -6.6 ± 7.2 | -3.1 ± 6.2 |
| End of maintenance period | -6.6 ± 7.2 | -3.0 ± 6.2 |
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.
| Percentage of participants | SPM962 | Placebo |
|---|---|---|
| ≥20% decrease (Week 2) | 35.2 (25.2 to 45.2) | 19.3 (11.1 to 27.6) |
| ≥20% decrease (Week 4) | 52.3 (41.8 to 62.7) | 28.4 (19.0 to 37.8) |
| ≥20% decrease (Week 6) | 62.5 (52.4 to 72.6) | 35.2 (25.2 to 45.2) |
| ≥20% decrease (Week 8) | 67.0 (57.2 to 76.9) | 37.0 (27.4 to 47.6) |
| ≥20% decrease (Week 10) | 70.5 (60.9 to 80.0) | 42.0 (31.7 to 52.4) |
| ≥20% decrease (Week 12) | 70.5 (60.9 to 80.0) | 40.9 (30.6 to 51.2) |
| ≥20% decrease (End of maintenance period) | 70.5 (60.9 to 80.0) | 40.9 (30.6 to 51.2) |
| ≥30% decrease (Week 2) | 22.7 (14.0 to 31.5) | 15.9 (8.3 to 23.6) |
| ≥30% decrease (Week 4) | 36.4 (26.3 to 46.4) | 21.6 (13.0 to 30.2) |
| ≥30% decrease (Week 6) | 52.3 (41.8 to 62.7) | 23.9 (15.0 to 32.8) |
| ≥30% decrease (Week 8) | 54.5 (44.1 to 64.9) | 28.4 (19.0 to 37.8) |
| ≥30% decrease (Week 10) | 58.0 (47.6 to 68.3) | 29.5 (20.0 to 39.1) |
| ≥30% decrease (Week 12) | 60.2 (50.0 to 70.5) | 28.4 (19.0 to 37.8) |
| ≥30% decrease (End of maintenance period) | 60.2 (50.0 to 70.5) | 28.4 (19.0 to 37.8) |
MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM962 | Placebo |
|---|---|---|
| Week 2 | -0.17 ± 0.46 | -0.01 ± 0.28 |
| Week 4 | -0.17 ± 0.75 | -0.11 ± 0.49 |
| Week 6 | -0.14 ± 0.89 | -0.13 ± 0.58 |
| Week 8 | -0.23 ± 0.89 | -0.07 ± 0.56 |
| Week 10 | -0.25 ± 0.91 | -0.11 ± 0.63 |
| Week 12 | -0.25 ± 0.91 | -0.05 ± 0.88 |
| End of maintenance period | -0.25 ± 0.91 | -0.05 ± 0.88 |
Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM962 | Placebo |
|---|---|---|
| Week 2 | 0.19 ± 0.45 | 0.09 ± 0.33 |
| Week 4 | 0.28 ± 0.79 | 0.08 ± 0.38 |
| Week 6 | 0.18 ± 0.54 | 0.03 ± 0.39 |
| Week 8 | 0.20 ± 0.61 | 0.09 ± 0.42 |
| Week 10 | 0.19 ± 0.62 | 0.03 ± 0.44 |
| Week 12 | 0.18 ± 0.64 | 0.05 ± 0.48 |
| End of maintenance period | 0.18 ± 0.64 | 0.03 ± 0.47 |
Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM962 | Placebo |
|---|---|---|
| Week 2 | -3.3 ± 5.9 | -2.1 ± 4.6 |
| Week 4 | -5.4 ± 7.1 | -3.8 ± 5.8 |
| Week 6 | -7.2 ± 8.7 | -4.7 ± 6.7 |
| Week 8 | -7.7 ± 9.4 | -4.6 ± 7.6 |
| Week 10 | -8.1 ± 9.6 | -4.7 ± 7.7 |
| Week 12 | -8.5 ± 9.9 | -4.1 ± 8.5 |
| End of maintenance period | -8.5 ± 9.9 | -4.1 ± 8.5 |
Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period. The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.
| Percentage of participants | SPM962 | Placebo |
|---|---|---|
| Increased | 8.1 | 9.1 |
| Not changed | 66.3 | 71.6 |
| Decreased | 25.6 | 19.3 |
Collected over 14 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPM962 | — | 2/90 (2.2%) | 73/90 (81.1%) |
| Placebo | — | 0/90 (0%) | 55/90 (61.1%) |
| Event | SPM962 | Placebo |
|---|---|---|
| Cerebral InfarctionVascular disorders | 1/90 | 0/90 |
| MyelopathyNervous system disorders | 1/90 | 0/90 |
| Event | SPM962 | Placebo |
|---|---|---|
| Application Site ReactionGeneral disorders | 42/90 | 20/90 |
| NauseaGastrointestinal disorders | 21/90 | 5/90 |
| NasopharyngitisInfections and infestations | 11/90 | 15/90 |
| VomitingGastrointestinal disorders | 14/90 | 1/90 |
| SomnolencePsychiatric disorders | 13/90 | 4/90 |
| ConstipationGastrointestinal disorders | 12/90 | 5/90 |
| ContusionInjury, poisoning and procedural complications | 1/90 | 7/90 |
| InsomniaPsychiatric disorders | 6/90 | 2/90 |
| RashSkin and subcutaneous tissue disorders | 0/90 | 6/90 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 4/90 | 2/90 |
Excluded 3 subjects (SPM962:2, placebo:1) because lack of assessment of efficacy, and 1 (plasebo) for not matching with the inclusion criteria.
| Age, Categorical(Participants) | SPM962 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 36 | 35 | 71 |
| >=65 years | 52 | 53 | 105 |
| Age, Continuous(years) | SPM962 | Placebo | Total |
|---|---|---|---|
| Mean | 65.1 ± 8.1 | 66.2 ± 7.9 | 65.6 ± 8.0 |
| Sex: Female, Male(Participants) | SPM962 | Placebo | Total |
|---|---|---|---|
| Female | 55 | 51 | 106 |
| Male | 33 | 37 | 70 |
| Region of Enrollment(participants) | SPM962 | Placebo | Total |
|---|---|---|---|
| Japan | 88 | 88 | 176 |
The record gives a start of Sep 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →